On September 8, 2024, I gave a talk at the 2024 Infectious Disease World Conference, presenting our study on the Hazan, Stone, and Babalola case series of hypoxemic COVID-19 patients, treated with ivermectin-based multidrug protocols. The conference had an in-person and an online session, and I opted to present with the online session. To squeeze everything into less than 25 minutes, I prerecorded the presentation, to ensure I don't go overtime. Since it came out OK, I am making the recording available via this Substack post, Rumble, and Telegram.
The presentation is focused on reviewing the details of the three case series, the protocols used, the case series demographic characteristics, and our statistical analysis establishing the strength of association between treatment and reduction in hospitalizations and deaths. We summarize the main lessons learned by our study. Not included in the presentation are the exact Fisher test tables, the details of our argument supporting the Bradford Hill criterion of coherence, and our review of the epistemology that underlies the Bradford Hill criteria. For the full story, you should read the paper.
This is a shortened presentation with more emphasis on the treatment protocols and less emphasis on the mathematical details. Sadly, despite the available data, medical doctors using ivermectin to treat COVID-19 continue to be harassed by medical boards.
The slides of the presentation are available below in both color and black-and-white format.
References
1. E. Gkioulekas, P.A. McCullough, C. Aldous: "Critical appraisal of multi-drug therapy in the ambulatory management of patients with COVID-19 and hypoxemia", preprint
2. J.C. Stone, P. Ndarukwa, D.E. Scheim, BM Dancis, J. Dancis, M.G.Gill, C. Aldous, "Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours", Biologics. 2022 2(3) (2022), 196-210.
3. S. Hazan, S. Dave, A.W. Gunaratne, S. Dolai, R.L. Clancy, P.A. McCullough, T.J. Borody, "Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients", Future Microbiology 17 (5) (2022), 339-350
4. O.E. Babalola, Y.A. Ndanusa, A.A. Ajayi, J.O. Ogedengbe, Y. Thairu, and O. Omede, "A Randomized Controlled Trial of Ivermectin Monotherapy versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in COVID- 19 Patients in Nigeria", Journal of Infectious Diseases and Epidemiology 7 (2021), 233
5. E. Gkioulekas, P.A. McCullough, V. Zelenko: "Statistical analysis methods applied to early outpatient COVID-19 treatment case series data", COVID 2(8) (2022), 1139-1182
Share this post